771579-40-9

Upstream product

• 39895-56-2 4-hydroxymethyl-benzylamine 

Relevant academic research and scientific papers

Structure-guided optimization of 1H-imidazole-2-carboxylic acid derivatives affording potent VIM-Type metallo-β-lactamase inhibitors

Production of metallo-β-lactamases (MBLs) in bacterial pathogens is an important cause of resistance to the ‘last-resort’ carbapenem antibiotics. Development of effective MBL inhibitors to reverse carbapenem resistance in Gram-negative bacteria is still needed. We herein report X-ray structure-guided optimization of 1H-imidazole-2-carboxylic acid (ICA) derivatives by considering how to engage with the active-site flexible loops and improve penetration into Gram-negative bacteria. Structure-activity relationship studies revealed the importance of appropriate substituents at ICA 1-position to achieve potent inhibition to class B1 MBLs, particularly the Verona Integron-encoded MBLs (VIMs), mainly by involving ingenious interactions with the flexible active site loops as observed by crystallographic analyses. Of the tested ICA inhibitors, 55 displayed potent synergistic antibacterial activity with meropenem against engineered Escherichia coli strains and even intractable clinically isolated Pseudomonas aeruginosa producing VIM-2 MBL. The morphologic and internal structural changes of bacterial cells after treatment further demonstrated that 55 crossed the outer membrane and reversed the activity of meropenem. Moreover, 55 showed good pharmacokinetic and safety profile in vivo, which could be a potential candidate for combating VIM-mediated Gram-negative carbapenem resistance.

Application of 1-substituted-1H-imidazole-2-carboxylic acid compounds in preparation of metal beta-lactamase inhibitors

The invention relates to application of 1-substituted-1H-imidazole-2-carboxylic acid compounds in preparation of metal beta-lactamase inhibitors, and particularly discloses application of compounds shown in a formula I in preparation of metal beta-lactamase inhibitors or antibacterial combined medicines. Experiments prove that the compounds provided by the invention can be used for effectively inhibiting the activity of various MBL enzymes including VIM-2, NDM-1, IMP-1, VIM-1 and VIM-5; the compounds, especially the compounds 11, 13, 14, 29, 30, 34, 37 and 40, have an IC50 value of 2.13 [mu] Mor less on the VIM-2 type MBL enzymes, have a more significant inhibition effect than positive control drugs, and have very good potential in the preparation of MBL enzyme inhibitors. Meanwhile, thecompounds disclosed by the invention are combined with beta-lactam antibiotics, so that metal beta-lactamase generated by drug-resistant bacteria can be effectively inhibited, the antibacterial activity of the antibiotics is enhanced, and the compounds have a very good application prospect in preparation of antibacterial combined medicines.

1 - Substituted - 111H-imidazol -2 - carboxylic acid compound (by machine translation)

The invention relates to 1 - substituted - 111H-imidazol -2 - carboxylic acid compounds. Experiments prove that the compound provided by the invention can effectively inhibit the activity of various MBL enzymes including VIM-2, NDM-1, ?currcurrcurrcurry ?, VIM-IMP-1 1 and VIM IM IM, especially compounds 11 and 13, 14, 29, 30, 34, 37, 40, and IC of VIM-2 type MBL enzyme. 50 The value is below 2.13 μm, the inhibition effect is more remarkable than that of the positive control medicine, and the MBL enzyme inhibitor has great potential in preparing the MBL enzyme inhibitor. , The compound is combined with β - lactam antibiotics, metal β - lactamase produced by drug-resistant bacteria can be effectively inhibited, the antibacterial activity of the antibiotic is enhanced, and the compound has a very good application prospect in preparation of antibacterial and combined medicines. (by machine translation)